Giving abatacept after checkpoint inhibitors can improve immunotherapy responses in melanoma
Giving abatacept after checkpoint inhibitors can improve immunotherapy responses in melanoma
Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100
Nivolumab plus platinum-doublet chemo vs chemo as neoadjuvant treatment for resectable NSCLC
Natural killer cells complexed with a bispecific antibody may provide new treatment option for patients with advanced lymphoma
Intratumoral BO-112 with pembrolizumab shows benefit in advanced melanoma refractory to anti-PD-1 therapy
Recurrent non-invasive breast tumours may not always be related to the primary lesion
Safety and efficacy of olaparib plus metronomic cyclophosphamide and metformin in advanced/metastatic endometrial cancer
Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid tumours
The adverse events atlas, towards a strategy to predict synergistic adverse events of combination therapies
Safety and efficacy of the oral ATR inhibitor elimusertib in advanced solid tumours with DNA damage response defects
PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations
Novel COVID-19 vaccine for B-cell deficient patients
Paediatric cancer patients in LMICS faced significantly higher mortality risk during the COVID-19 pandemic